Document is current
Any future updates will be listed below
-
Authors
Coursimault, Juliette
Guillon, Emilie
Lecoquierre, François
Charbonnier, Camille
Guerrot, Anne-Marie
Goldenberg, Alice
Nicolas, Gaël
Schaefer, Elise
Ayrolles, Anael
Delorme, Richard
Riccardi, Florence
Grelet, Maude
Caumes, Roseline
Nizon, Mathilde
Isidor, Bertrand
Jouret, Guillaume
Rooryck, Caroline
Amiel, Jeanne
Alaix, Anne-Sophie
Morel, Victor
Jacquinet, Adeline
Mignot, Cyril
Faivre, Laurence
Fraile-Caietta, Emilie
Chalopin, Sarah
Dubern, Béatrice
Poitou, Christine
- License Information
-
More Information
Article History
First Online: 21 July 2026
Declarations
Ethics approval and consent to participate: All patients gave their consent to participate in the study. This study expands on the 2022 cohort published by Coursimault et al., approved by the Institutional Review Board of the Rouen University Hospital (CERDE, Comité d’Ethique pour la Recherche sur Données Existantes et Hors Loi Jardé, Rouen, France) (notification n°69–2020). Some patients were included as part of the French Rare Obesity Cohorts With Food Behavioural Disorders: Better Diagnosis for Better Treatment (ObeRare) cohort (NCT04604626).
Consent for publication: Not applicable.
Competing interests: JC has nothing to disclose. All other collaborators do not have anything to disclose. BD has nothing to disclose. Rhythm Pharmaceuticals provided financial support for data entry in the ObeRar database but had no role in the scientific aspects of the study, including data analysis, results, or their interpretation.
